Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has filed a new patent application with the United States Patent and Trademark Office for the use of its DehydraTECH™ technology to improve the speed and quantity of absorption of active pharmaceutical ingredients through the skin. This update comes on the heels of Lexaria’s recently detailed successful laboratory evaluation of DehydraTECH™ in the transdermal delivery of cannabidiol. Per company data, the platform demonstrated as much as a 225 percent increase in CBD permeability when compared to control formulations featuring leading commercial penetration enhancers, as well as a nearly 1,900 percent increase in CBD permeability when compared to a control formulation that was devoid of any commercial penetration enhancer. This new patent application includes protection for the delivery of all of the active ingredient classes identified in Lexaria’s other issued and pending patent applications, including cannabinoids, terpenes and terpenoids, NSAIDs, vitamins, nicotine and phosphodiesterase inhibitors.
To view the full press release, visit http://cnw.fm/k1OZX
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaEnergy.com
More from CannabisNewsBreaks
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com